Skip to main content

Table 2 Adverse events with capecitabine adjuvant chemotherapy

From: Effectiveness of protocol-based pharmacotherapy management collaboration between hospital and community pharmacists to address capecitabine-related hand–foot syndrome in cancer patients: a retrospective study

Adverse events

Control group (n = 59)

PBPM group (n = 110)

p-value

Chemotherapy regimens

All (%)

Grade 0

Grade 1

Grade 2

Grade 3

All (%)

Grade 0

Grade 1

Grade 2

Grade 3

Hand-foot syndrome

59 (100)

25

31

3

0

110 (100)

66

39

5

0

0.0382

 XELOX

34 (57.6)

16

17

1

0

55 (50.0)

33

20

2

0

0.2720

 XELOX + Bevacizumab

16 (27.1)

6

9

1

0

30 (27.3)

18

12

0

0

0.1162

 Capecitabine

9 (15.3)

3

5

1

0

24 (21.8)

14

7

3

0

0.3135

 XELIRI + Bevacizumab

1 (0.9)

1

0

0

0

Constipation

42 (71.2)

36

5

1

0

44 (40.0)

43

1

0

0

0.0430

Diarrhea

44 (74.6)

43

1

0

0

51 (46.4)

45

6

0

0

0.3227

Nausea/vomiting

44 (74.6)

44

0

0

0

60 (54.5)

52

7

0

1

0.0124

Stomatitis

41 (69.5)

41

0

0

0

40 (36.4)

37

2

1

0

0.0782

Loss of appetite

43 (72.9)

42

1

0

0

66 (60.0)

52

10

4

0

0.0015

Fatigue

41 (69.5)

34

7

0

0

52 (47.3)

38

13

1

0

0.0010

Rash

36 (61.0)

36

0

0

0

37 (33.6)

37

0

0

0

NA

Fever

37 (62.7)

37

0

0

0

38 (34.5)

37

1

0

0

0.3370

Watering eyes

36 (61.0)

36

0

0

0

32 (29.1)

27

5

0

0

0.0150

Hypertension

57 (96.6)

57

0

0

0

110 (100)

109

1

0

0

0.4794

Peripheral neuropathy

57 (96.6)

49

7

1

0

47 (42.7)

2

39

5

1

1.0040

  1. Abbreviation: XELOX, capecitabine plus oxaliplatin: XELIRI, capecitabine plus irinotecan: NA, not applicable